Mammary Cell News Volume 12.03 | Jan 30 2020

TOP STORY

RIPK3 Upregulation Confers Robust Proliferation and Collateral Cystine-Dependence on Breast Cancer Recurrence

Scientists found that RIPK3, while absent in primary tumor cells, was dramatically reexpressed in recurrent breast tumor cells by an epigenetic mechanism. They found that RIPK3 knockdown in recurrent tumor cells reduced clonogenic growth, causing cytokinesis failure, p53 stabilization, and repressed the activities of YAP/TAZ. [Cell Death Differ] Abstract

(Ranked by impact factor of the journal)

Rapid Detection of Circulating Breast Cancer Cells Using a Multi-Resonant Optical Fiber Aptasensor with Plasmonic Amplification

Specific aptamers against mammaglobin-A were selected and immobilized as receptors on the sensor surface. In vitro assays confirmed that label-free and real-time detection of cancer cells occured within five minutes. [ACS Sensors] Abstract

Cytokeratin 5 Alters β-Catenin Dynamics in Breast Cancer Cells

Investigators established through cytokeratin 5 (CK5) knockout and overexpression in estrogen receptor⁺ breast cancer cell lines that CK5 was important for tumorsphere formation, prompting them to speculate that CK5 had regulatory activity in cancer stem cells. [Oncogene] Abstract

Zinc Finger Protein 367 Promotes Metastasis by Inhibiting the Hippo Pathway in Breast Cancer

ZNF367 was upregulated in breast cancer tissues and cell lines, and significantly correlated with poorer metastasis-free and overall survivals in patients. ZNF367 promoted tumor metastasis accompanied with increase of circulating tumor cells numbers. [Oncogene] Abstract

Lipoic Acid Decreases Breast Cancer Cell Proliferation by Inhibiting IGF-1R via Furin Downregulation

The authors demonstrated that lipoic acid inhibited the proliferation and Akt and ERK signaling pathways of several breast cancer cells. While searching for upstream dysregulations, they discovered the loss of expression of IGF-1R upon exposure to lipoic acid. [Br J Cancer] Abstract

Hypoxic Environment May Enhance Migration/Penetration of Endocrine Resistant MCF7- Derived Breast Cancer Cells through Monolayers of Other Non-Invasive Cancer Cells In Vitro

Scientists found that the expression and nuclear translocation of hypoxia inducible factor 1α was significantly elevated by hypoxia, which inhibited cell proliferation, but significantly increased motility of estrogen receptor negative cells. [Sci Rep] Full Article

The Mechanism of How CD95/Fas Activates the Type I IFN/STAT1 Axis, Driving Cancer Stemness in Breast Cancer

Chronic stimulation of CD95 on breast cancer cells could increase their cancer initiating capacity through activation of a type I interferon/STAT1 pathway when caspases were inhibited. [Sci Rep] Full Article

Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Novel Curcumin Analogues in Paclitaxel-Resistant Human Breast Cancer Cells

Four P-glycoprotein (P-gp) modulators were evaluated for their activity in a P-gp overexpressed breast cancer cell line LCC6MDR. The four modulators displayed significantly better P-gp modulating activity compared to the positive control verapamil. [Biochem Cell Biol] Abstract

MTSS1 Suppresses Mammary Tumor-Initiating Cells by Enhancing RBCK1-Mediated p65 Ubiquitination

Scientists report a role of metastasis suppressor protein 1 (MTSS1) in suppressing tumor-initiating cells in breast cancer. MTSS1 suppressed tumorsphere formation in breast cancer cells. [Nat Cancer] Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Critical Roles of Long Noncoding RNAs in Breast Cancer

The authors elicit the significance of long noncoding RNAs in the regulation of cell signaling pathways, and the resulting changes in cell survival, proliferation, and invasion, which are the hallmarks of breast cancer. [J Cell Physiol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Syros Announces First Patient Dosed in Phase I Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors

Syros Pharmaceuticals announced that the first patient has been dosed in the Phase I clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 inhibitor. [Syros Pharmaceuticals, Inc.] Press Release

The American Cancer Society and Pfizer Launch Community Grants Focused on Racial Disparities in Breast Cancer Mortality

The American Cancer Society and Pfizer have approved grants totaling more than $2.5 million in nine communities focused on reducing racial disparities and helping optimize outcomes for women facing a breast cancer diagnosis. The grants, funded by Pfizer Global Medical Grants and overseen by the American Cancer Society, are the first in the Integrated Approach to Breast Health Equity Competitive Grant Program, a three-year collaboration working to promote equitable outcomes for all women living with breast cancer [The American Cancer Society (PR Newswire Association LLC.)] Press Release

UK and EU: Cherish What You Have Achieved and Stay Close

Most scientists didn’t want Brexit. UK researchers do not yet know if they will be part of joint EU research programs. However, in one piece of welcome news, the futures of the many EU researchers who want to make their lives in Britain now lie in the hands of the UK Research and Innovation agency, and not the UK Home Office – an institution that, for much of the past decade, enacted and implemented policies to reduce immigration to the United Kingdom. [Nature News] Editorial

Top Harvard Chemist Charged with Lying about Ties to Chinese Government Program

The head of Harvard University’s chemistry department was charged with attempting to conceal his involvement in a Chinese government program to bring scientists to China, an escalation of a crackdown by US authorities on what they perceive as a campaign to steal ideas born in American universities and medical centers. [STAT News] Editorial

NEW American Association for Cancer Research (AACR) Annual Meeting 2020
April 24-29, 2020
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Associate Director – Translational Science in Breast Cancer (AstraZeneca)

NEW Postdoctoral Fellow – Breast Tumorigenesis (University of Cincinnati)

Research Fellow – Anti-Cancer Therapy (Mayo Clinic)

Postdoctoral Position – DNA Nanotechonology in Cancer (University of Duisburg-Essen)

Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute)

Postdoctoral Fellowship – Breast Cancer Immunology and Immunotherapy (The University of Texas Southwestern)

Investigator Position – Cancer Cell Biology (Winthrop P. Rockefeller Cancer Institute)

Postdoctoral Research Fellow – Breast Cancer Research (University of South Carolina)

Postdoctoral Fellow – Brain Metastasis in Aggressive Breast Cancers (The University of Texas MD Anderson Cancer Center)

Postdoctoral Research Scientist – Metabolism and Epigenetics in Breast Cancer (The Cancer Research UK Beatson Institute)

Leader – Breast Cancer Program (Fred Hutchinson Cancer Research Center)

Assistant Professor – The Department of Breast Medical Oncology (The University of Texas MD Anderson Cancer Center)

Postdoctoral Associate – Immune Responses (The Jackson Laboratory)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.